Reference Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

Ref Type
PMID
Authors Feng Wang
Title Abstract 4903: AXL inhibition overcomes erlotinib resistance in AXL-activated non-small cell lung cancer cells
URL http://cancerres.aacrjournals.org/content/78/13_Supplement/4903
Abstract Text

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Treatment Approach
Gene Name Source Synonyms Protein Domains Gene Description Gene Role
Therapy Name Drugs Efficacy Evidence Clinical Trials
Drug Name Trade Name Synonyms Drug Classes Drug Description
Gene Variant Impact Protein Effect Variant Description Associated with drug Resistance
AXL A273V missense unknown AXL A273V lies within fibronectin type-III domain 1 of the Axl protein (UniProt.org). A273V has been associated with resistance to EGFR inhibitors (Cancer Res 2018;78(13 Suppl): nr 4903), but has not been biochemically characterized and therefore, its effect on Axl protein function is unknown (PubMed, Jan 2026). Y
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
AXL A273V lung non-small cell carcinoma predicted - resistant Erlotinib Preclinical - Cell culture Actionable In a preclinical study, expression of AXL A273V in non-small cell lung cancer cells conferred resistance to Tarceva (erlotinib) in culture (Cancer Res 2018;78(13 Suppl): nr 4903). detail...